Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Abramov Dror Yosef reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Abramov Dror Yosef reported equity awards on February 20, 2026. He received 9,091 ordinary shares through a grant of fully vested restricted share units that were immediately settled into shares for his director services, as approved by the board.
He was also granted 10,685 stock options to buy ordinary shares, with these options vesting in full on the one-year anniversary of the board’s approval date and expiring ten years after that approval. Following these awards, he held 10,180 ordinary shares directly, and a separate line shows 935 stock options as an existing holding included for informational purposes.
Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.
On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.
Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner, received equity awards for director services. The fund was granted 9,091 ordinary shares via fully vested RSUs and 10,685 stock options. These options vest in full on the one-year anniversary of board approval and expire ten years after that approval date. An additional 1,872 stock options are reported as existing holdings with no new transaction.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.
Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of December 31, 2025.
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.
Silexion Therapeutics Corp is calling an extraordinary general meeting to ask shareholders to approve a large increase in its authorized share capital and a bigger automatic share pool for equity incentives. The company proposes raising authorized ordinary shares from 9,000,000 to 59,000,000, adding 50,000,000 new authorized shares at the same par value. Management explains this is needed to maintain compliance with Nasdaq’s minimum $2.5 million shareholders’ equity requirement and to fund pre-clinical and clinical development of its RNAi therapies and potential business development deals. Silexion also seeks to amend its 2024 Equity Incentive Plan so that, starting January 1, 2026, the annual “evergreen” increase keeps all equity incentive plans at 10% of fully diluted shares, instead of a fixed 5% of outstanding shares. Both proposals require approval by an ordinary majority of votes cast, and the board unanimously recommends voting in favor.
Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.
Silexion Therapeutics Corp insider entities led by Ilan Levin and Moringa Sponsor, LP reported several share and warrant changes. On August 7, 2025, Moringa Sponsor, LP made a pro rata distribution of 5,550 ordinary shares and 935 warrants to its limited partners for no consideration, leaving 6,970 ordinary shares and 372 warrants indirectly held through that entity. On September 15, 2025, Moringa Sponsor, LP received 450,000 ordinary shares upon conversion of $1,800,000 of principal under a convertible promissory note at $4.00 per share, an issuance approved by the board.
The reporting persons state they dispute the validity of this 450,000-share issuance and do not concede beneficial ownership of those shares. The filing also notes 1-for-9 and 1-for-15 reverse share splits that reduced reported share and warrant counts, and includes 1,482 ordinary shares held via Greenstar, L.P. for informational purposes.
Silexion Therapeutics Corp announced it has submitted a Phase 2/3 clinical trial application in Israel for SIL204 in locally advanced pancreatic cancer. This step indicates the company is preparing to test SIL204 in a more advanced clinical setting, combining elements of mid- and late-stage evaluation.
The update was shared through a press release furnished under a Regulation FD disclosure, meaning the company is providing the same information to all market participants at the same time.
Silexion Therapeutics Corp filed a current report to share news about its pancreatic cancer program. On December 2, 2025, the company issued a press release titled “Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer.” This indicates that a German health authority has responded favorably to the company’s proposed design for a Phase 2/3 study, an important planning step before running a larger, later-stage trial.
The company is furnishing this press release under a Regulation FD disclosure, meaning it is providing the information broadly to the market. The disclosure is explicitly described as “furnished” rather than “filed,” so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.